[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"AB Biotics, SA\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":134},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,80,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100607851","phase-2-investigation-of-the-efficacy-of-a-probiotic-mixture-in-moderate-metabolic-dysfunction-associated-steatotic-liver-disease-masld-a-mechanistic-trial-100607851",false,"NCT07193927","Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial","Investigation of the Efficacy of a Probiotic Mixture in Subjects With Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial","Inclusion Criteria:\n\n* Patients aged from 18 to 75 years old\n* BMI 25 - 42kg\u002Fm2\n* Diagnosed with MASLD and CAP value \\> 268 dB\u002Fm evaluated by FibroScan®\n* High ALT levels (\\>30 U\u002FL in males and \\>19 U\u002FL in females)\n* Having at least three of the following features compatible with metabolic syndrome:\n\n  i. Waist circumference ≥ 102 cm in males and ≥ 88 cm in females. ii. Fasting serum glucose (≥ 5.6 mmol\u002FL or 100 mg\u002Fdl). iii. Glycated haemoglobin (HbA1c ≥ 5.7%\u002F 39 mmol\u002FL). iv. Diagnosed or treated for type 2 diabetes. v. High blood pressure (≥ 130\u002F85 mmHg). vi. High plasma triglycerides (≥ 1.70 mmol\u002FL or 150 mg\u002Fdl). vii. Lower plasma of High-Density Lipoprotein (HDL cholesterol) (≤ 1.0 mmol\u002FL or 40 mg\u002Fdl for males and ≤ 1.3 mmol\u002FL or 50 mg\u002Fdl for females).\n* Stable weight in the last 3 months (less than ± 4% weight variation).\n* Stable medication or intake of food supplements for a medical condition that can affect study outcomes according to the Investigator's judgement in the last three months prior to study entry (bile salt sequestrants are not permitted).\n* Not planning to change their dietary and lifestyle habits during the study.\n* Willing and able to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Fibrosis scores equal or higher than F2 (≥ 8.0 kPa).\n* History of acute or chronic hepatitis A, B or C, autoimmune hepatitis, drug-induced liver diseases, severe liver diseases.\n* Prior or pending liver transplantation.\n\nPatients with at least one of the following concurrent conditions:\n\ni. Type I diabetes ii. Uncontrolled type II diabetes (HbA1c \\>8%) iii. Hypertriglyceridemia \\> 350mg\u002Fdl iv. Human Immunodeficiency Virus (HIV) infection v. Diagnosis of hemochromatosis\n\n* Current use of pioglitazone, SGLT-2 inhibitors, or approved drugs for MASLD or steatohepatitis within 8 weeks.\n* Current use of bile salt sequestrants within 8 weeks.\n* Significant gastrointestinal disease, such as inframmatory bowel disease (IBD, short bowel syndrome, chronic or recurrent diarrhoea, coeliac condition.\n* Pancreatic failure, biliary dysfunction (including cholecystectomy and blood bilirubin abnormalities)\n* Thyroid dysfunction, as assessed by the investigator (clinical criteria)\n* History of:\n\n  i. Cardiovascular disease (ischemic heart disease, heart failure, cerebrovascular disease, periphreal vascular disease).\n\nii. Cancer or immunosuppression. iii. Gastrointestinal surgery in the previous year (with the exception of appendicitis).\n\n* Patients with a history of chronic alcohol or drug abuse: \\> 14 units\u002Fweek for females and \\> 21 units\u002Fweek for male\n* Chronic and heavy smoking (\\>20 cigarettes a day)\n* Regular intake (\\> 3 days\u002Fweek) of other probiotics (including food complements or diary foods with other probiotic strains, e.g. Activia®, Actimel® or similar).\n* Intake of nutraceuticals with an effect on hepatic function such as \\> 500 mg\u002Fday omega-3 fatty acids, high-dose vitamin E supplements or milk thistle (sylibum marianum) extract ot their active ingredients (silymarin, silybin) regularly (\\> 7 days) in the 15 days before study entry.\n* Current use of systemic corticosteroids, androgens, clopidogrel, digoxin, acenocoumarol, warfarin, phenytoin, topiramate, lithium, tricyclic antidepressants, MAOIs or second-generation antipsychotics, amiodarone, tamixofen and\u002For diltiazem.\n* History of use (\\> 3 days) of oral or parenteral antibiotics one month before the study initiation.\n* Chronic use of laxatives.\n* Debilitating illnesses (advanced liver or kidney disease, severe depression, psychotic symptoms, neurological diseases).\n* Current pregnancy (positive urine test) or planning to become pregnant during the study.\n* Breastfeeding at the time of eligibility assessment.\n* Patients who have participated in a clinical trial in the six-month period before the study.","ALL","18 Years","75 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to evaluate whether a specific probiotic mixture can improve liver health in adults with moderate metabolic dysfunction-associated steatotic liver disease (MASLD).\n\nThe main questions it aims to answer are:\n\nCan the probiotics improve liver fat and stiffness as measured by non-invasive imaging (FibroScan® CAP and FAST scores)? Does the probiotic affect other health markers like cholesterol, blood sugar, inflammation, and gut bacteria?\n\nResearchers will compare people taking the probiotic to those taking a placebo (a capsule with no active ingredients) to see if the probiotic has beneficial effects.\n\nParticipants will:\n\nBe randomly assigned to take either the probiotic or placebo daily for 6 months.\n\nAttend 3 study visits (at the start, 3 months, and 6 months). Provide blood and stool samples. Undergo liver scans (FibroScan®). Complete a health and nutrition questionnaire.\n\nThis study includes adults aged 18-65 with moderate MASLD and certain metabolic health conditions. Participants must not be pregnant, breastfeeding, or taking certain medications or supplements that could interfere with the study.",[27,28,29],"MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Fatty Liver Disease, Nonalcoholic","Overweight (BMI > 25)","RECRUITING","2026-04-29",{"date":33,"type":34},"2026-04-30","ACTUAL",{"date":36,"type":34},"2026-03-20",{"date":38,"type":21},"2027-06-01",{"name":40,"class":41},"AB Biotics, SA","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100627891","examine-impact-of-topical-application-of-active-versus-placebo-on-the-skin-microbiome-in-sensitive-skin-100627891","NCT07454525","Examine Impact of Topical Application of Active Versus Placebo on the Skin Microbiome in Sensitive Skin.","SkinBiome","Inclusion Criteria:\n\n* Women aged 40-60 among all ethnicities and Fitzpatrick scale.\n* With self-assessed sensitive skin (SS10 \\> 13) and self-reported mild to moderate fine lines and wrinkles.\n* Must spend minimum 1 hour outside from 10am-4pm at least 5 times per week.\n* Residing within the same country on the mid to west coast (California, Nevada, Utah, Arizona, Colorado, New Mexico, Kansas, Oklahoma, Texas, Illinois, Kansas, Idaho, Nebraska, Montana).\n* Consider themselves to be in good health.\n* Willing to continue to use their current cosmetic products (foundation, blush, eyeshadow, sunscreen, etc.) and with the same routine\u002Ffrequency if they do not contain anti-aging ingredients.\n* Willing to refrain from using AHA, other peeling acids (PHA, BHA), prescription products such as retinoids or hydroquinone etc. during the study.\n* Willing to take skin swabs to support measures of the skin microbiome.\n* Must understand their role in the study, provide written informed consent, and fully participate over the 14-week period.\n* Willing to use the products provided within the study as instructed. Willing to change their current skincare routine and replace it with the given regimen for 14 weeks.\n* Willing to maintain diet and lifestyle (including physical exercise) during study period.\n\nExclusion Criteria:\n\n* Used any of the products to be tested in the claim study in the past 3 months. - Participation in a similar skin study within the past 30 days.\n* Have active skin disorders such as psoriasis, eczema, allergies, wounds, scars, or severe acne on their forehead.\n* Regular use of probiotic supplements\n* Consumption of fermented foods (including kefir, probiotic containing yoghurt, kombucha or other) for more than 5 times a week\n* Are orally or topically using or have used in the past 6 months: antibiotics, NSAIDS, antihistamines, immuno-suppressants, corticosteroids, prescription products such as retinoids, hydroquinone, or strong AHA treatments.\n* Have started hormonal treatment (e.g., contraceptives, fertility treatments, or HRT for menopause) within the past 3 months or in case they are on a treatment for more than 3 months they are unwilling to maintain a stable regimen for the duration of the study.\n* Pregnant or breastfeeding.\n* Any history of significant disease or medical condition to alter skin appearances such as type 2 diabetes, cancer, renal disorders or hepatic dysfunction.\n* Individuals who have had medical procedures in their face such as laser resurfacing (or any type of laser treatment ex. photo depilation), plastic surgery (including Botox) within the last 12 months or history of UV radiation (tanning and facial lamps) within the last 3 months.\n* Active Vitiligo or any other chronic skin conditions.\n* Individuals with any history that, in the investigator's opinion, indicates potential harm to the subject or could jeopardize the validity of the study.\n* History of poor cooperation, non-compliance, unreliability, or unwillingness to follow the research protocol and timeline.",true,"FEMALE","40 Years","60 Years",{"count":55,"type":21},45,[57],"NA","The purpose of this study is to build insights to understand how the placebo and active impacts the skin microbiome in women with high skin sensitivity (SS10 \\> 13) and sun exposure. Microbiome samples will be taken at baseline after 2 weeks of using the placebo (base without active) as a run-in period followed by the usage of placebo for an additional 4 weeks. The participants will then start the usage of active formula for an additional 8 weeks with microbiome samples collected at the 10-week and 14-week. This will allow us to observe how the microbiome changes over time after the product usage of both placebo and active formulations relative to the pre-regimen condition. In addition, headshot photos will be taken using the Haut AI application at each time point concurrent to the microbiome sample collection to examine changes in skin appearances after the regimen.",[60,61,62,63],"Skin","Skin Microbiome","Skin Microbiota","Skin Ageing",[65,60,66,67,68,69,70],"Microbiome","Skin ageing","Fine lines","Face Skin","Sun exposure","Skin appearance","NOT_YET_RECRUITING","2026-03-04",{"date":74,"type":34},"2026-03-06",{"date":76,"type":21},"2026-02",{"date":78,"type":21},"2026-06",{"name":40,"class":41},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":50,"sex":51,"minAge":88,"maxAge":53,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100619355","clinical-trial-to-assess-the-efficacy-and-safety-of-a-cosmetic-product-in-individuals-showing-signs-of-cutaneous-aging-100619355","NCT07343544","Clinical Trial to Assess the Efficacy and Safety of a Cosmetic Product in Individuals Showing Signs of Cutaneous Aging.","Estudio clínico Para Evaluar Los Efectos y la Seguridad de un Producto cosmético en Sujetos Con Signos de Envejecimiento cutáneo.","SkinMeter","Inclusion Criteria:\n\n* Female participants.\n* Age between 35 and 60 years.\n* All skin types (combination, oily, dry, and\u002For normal).\n* Skin condition: 50% sensitive skin and 50% normal skin.\n* Visible signs of facial skin aging (mild\u002Fmoderate wrinkles and\u002For pigmentation spots).\n* Willingness to participate voluntarily and provide written informed consent.\n* Ability to understand the study objectives and procedures.\n* Good general health (physical and mental).\n* Availability to attend all scheduled visits at the research center.\n* Discontinuation of anti-aging products on the experimental area (face) at least 7 days prior to study start.\n* Commitment not to change facial hygiene routines during the study.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* History of allergy to cosmetic products and\u002For dietary supplements.\n* Known allergy or hypersensitivity to any component of the product.\n* History or current diagnosis of cancer.\n* Active skin diseases or infections in the experimental area.\n* Recent or planned surgical or aesthetic interventions in the experimental area Medical-aesthetic treatments on the face within the last 6 months (e.g., botulinum toxin, hyaluronic acid, laser, radiofrequency, HIFU, deep chemical peels, microneedling with actives).\n* Relevant dermatological conditions in the experimental area (eczema, psoriasis, allergic\u002Fcontact dermatitis, etc.).\n* Use of topical or systemic medications affecting the skin (retinoids, antibiotics, corticosteroids) within the last 3 months.\n* Current or planned use of supplements that may affect skin health (collagen, antioxidant vitamins A\u002FC\u002FE, zinc, omega-3, oral probiotics\u002Fprebiotics).\n* Systemic diseases such as autoimmune disorders (rheumatoid arthritis, lupus, multiple sclerosis), chronic viral infections (HIV, hepatitis B\u002FC), or severe metabolic diseases.\n* Use of any product other than the study product on the experimental area during the study.\n* Planned significant changes in health habits during the study (diet, physical activity, structured exercise programs).\n* Recent or planned changes in hormonal contraceptives.\n* Sun or UVA exposure during the study.\n* Participation in another clinical study involving the same experimental area\n* Application of any product on the experimental area on the day of study initiation.\n* Any medical condition, at the investigator's discretion, that may interfere with protocol adherence or participant safety.","35 Years",{"count":55,"type":21},[57],"This clinical study investigates the effects and safety of a topical cosmetic product containing postbiotics (Bifida ferment extract and Pediococcus ferment extract) in women aged 35-60 with visible signs of skin aging.\n\nThe study is a 3-month, single-center, intra-subject controlled trial involving 45 Caucasian women with sensitive or normal skin. Participants will apply 1 ml of the product twice daily. Clinical evaluations will be conducted at baseline and at 1 month, 2 months, and 3 months, using validated dermatological scales and non-invasive instruments (AEVA3D, Mexameter®, MoistureMap®, Cutometer®, Tewameter®, Clarius®, Glossymeter®).\n\nSafety will be assessed through systematic monitoring of adverse events, with serious adverse events expected to remain below 1%. Subjective perception will be evaluated via structured questionnaires.",[60,63,93,94,95],"Fine Lines","Face Aging\u002FPhoto Aging of Moderate Grade","Face Skin Photoaging",[68,97,60,66],"Postbiotics","2026-01-08",{"date":100,"type":34},"2026-01-15",{"date":76,"type":21},{"date":103,"type":21},"2026-05",{"name":40,"class":41},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":50,"sex":16,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},"100479566","effect-of-probiotics-on-infants-fecal-microbiota-composition-100479566","NCT05524649","Effect of Probiotics on Infant's Fecal Microbiota Composition","Safety, Tolerability and Effect on Fecal Microbiota Composition of Two Probiotic Strains in Infants","BABYCARE","Inclusion Criteria:\n\n* Healthy infants\n* Age between 1 and 90 days\n* Gestational age between 37 and 42 weeks\n* Appropiate birth weight for gestational age (between P10 and P90)\n* APGAR test score for birth normal at 1' and 5' of 7-10\n* Whose parents accept the follow-up of the study procedures and sign the informed consent\n\nExclusion Criteria:\n\n* Infants participating in other clinical study\n* Fed with infant formula containing probiotics or other aliments or food supplement based in probiotics 4 weeks prior the start of the study\n* Infants who have taken antibiotics 4 weeks prior the start study\n* Infants with cow's milk protein allergy, lactose intolerance or other digestive diseases\n* Mother's pathological background and during gestation: neurologic disorders, matabolopaties, diabetes mellitus type 1, chronic disease (hypothyroidism), maternal malnutrition\n* Acute congenital or acquired diseases which can interfere with the growth and the normal feeding of the infant\n* TORCH complex infections\n* Every other diseases related with the immune system\n* Parents who can not accomplish the follow-up of the study (medical criterium)","1 Day","90 Days",{"count":116,"type":21},120,[57],"Randomized clinical trial to evaluate the effect of two probiotic strains which belong to Bifidobacterium Longum and Pediococcus pentosaceus species on fecal microbiota composition in healthy infants. Secondary outcomes comprise evaluation of anthropometric growth, digestive tolerance, sleeping habits, incidence of functional gastrointestinal disorders, incidence of gastrointestinal and respiratory infections, allergic reactions and safety and tolerability of the product.",[120],"Microbial Colonization",[122,123,124],"Probiotics","Infants","Microbiota","2025-02-10",{"date":127,"type":34},"2025-02-11",{"date":129,"type":34},"2022-06-01",{"date":131,"type":21},"2025-12-31",{"name":40,"class":41},2,""]